Company profile
Niagen Bioscience Inc
NASDAQ: NAGE · Healthcare · Biotechnology
#325 of 1,418 Healthcare companies by revenue71st-percentile growth
EA Score
78B+FH 86DQ 71GM 76SS 62
v0.1 · 65/100 weight · provisional
↑ return on assets, return on equity · ↓ listing tenure, disclosure history
Methodology →Revenue TTM
$129.1M
Rev growth YoY (TTM)
+11.0%
Net income (FY)
$17.4M
Employees
117
as of 2026-08-13
Market cap
$243.7M
as of 2026-08-13
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$129.4M$129.4M2025
Net income$17.4M$17.4M2025
Operating income$16.3M$16.3M2025
Total assets$106.4M$106.4M2025
Liabilities$29.9M$29.9M2025
Equity$76.5M$76.5M2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Niagen Bioscience Inc’s revenue?
Niagen Bioscience Inc booked $129.4M in FY2025 revenue, growing 30% year over year — faster than most Healthcare companies we track, at a 13.4% net margin.
Peers · Healthcare
RxSight, Inc.59CXtant Medical Holdings, Inc.74BUpHealth, Inc.——Xencor, Inc.59CMonte Rosa Therapeutics, Inc.54DAtara Biotherapeutics, Inc.44DNeighbors
Los Angeles →Key facts
CEORobert N. Fried
SectorHealthcare
IndustryBiotechnology
HeadquartersLos Angeles, CA
ExchangeNASDAQ: NAGE
Employees117
IPO date2015-06-24
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.